PF-07054894

PF-07054894 is an orally active and potent C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) antagonist that blocks CCR6-mediated chemotaxis with an IC50 value of 5.7 nM in vitro. PF-07054894 targets G protein-coupled receptor (GPCR) . PF-07054894 can be used in research of inflammatory bowel disease[1][2][3][4].

Product Specifications

CAS Number

[2413693-96-4]

UNSPSC

12352005

Target

CCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pf-07054894.html

Concentration

10mM

Purity

99.15

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=C(C(N(C)C)=O)N=CC=C1NC2=C(N[C@@H](C3=NN(C)C=C3C)C4(C)CCCC4)C(C2=O)=O

Molecular Formula

C24H30N6O4

Molecular Weight

466.53

References & Citations

[1]Gómez S, et, al. Desarrollo de anticuerpos terapéuticos contra el receptor CCR6 humano. |[2]Li W, et al. A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6+ T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation. J Pharmacol Exp Ther. 2023 Jul;386 (1) :80-92. |[3]Li W, et al. A novel CCR6 antagonist (PF-07054894) that distinguishes between homologous chemokine receptors, increases basal circulating CCR6+ T cells, and ameliorates interleukin-23-induced skin inflammation[J]. Journal of Pharmacology and Experimental Therapeutics, 2023. |[4]Chinigo G M, et al. Early Process Development of PF-07054894, a Squaramide-Based Antagonist of C–C Chemokine Receptor Type 6 (CCR6) [J]. Organic Process Research & Development, 2024.